What are GLP-1 weight-loss medications?
GLP-1 receptor agonists mimic a gut hormone that helps regulate appetite and fullness, often lowering calorie intake. Some newer options (e.g., tirzepatide) also act on GIP receptors, which may further enhance effects. These medications are meant to be used with reduced-calorie eating and increased activity—not as a stand-alone fix.
Key takeaways
Most evidence-based today: Semaglutide 2.4 mg (Wegovy) and tirzepatide (Zepbound) used alongside diet and activity.
Typical clinical results: About ~15% average body-weight loss with semaglutide; ~15–21% with tirzepatide (dose-dependent). Individual results vary.
Important safety notes: Class boxed warning for thyroid C-cell tumors (rodent data). Do not use if you or family have MTC or MEN2; discuss pancreatitis/gallbladder history with your clinician.
Approved options for chronic weight management
Wegovy® (semaglutide 2.4 mg, weekly) — GLP-1 RA indicated for adults with BMI ≥30, or ≥27 with a weight-related condition.
Zepbound® (tirzepatide, weekly) — Dual GIP/GLP-1 agonist for adults with obesity or overweight plus a comorbidity; titration starts low and steps up.
Saxenda® (liraglutide, daily) — GLP-1 RA; adult use and certain adolescents (≥12 years, >60 kg); typically less weight loss than the newer agents.
Make the lifestyle part easy: Get your personalized calories, macros & workouts
How effective are they?
Semaglutide 2.4 mg (Wegovy): Trials report ~15% mean body-weight loss over ~68 weeks when combined with lifestyle support.
Tirzepatide (Zepbound): ~15–21% mean loss over ~72 weeks, with higher doses producing greater reductions.
Head-to-head: Recent research suggests tirzepatide may yield greater average loss vs semaglutide in adults with obesity and no diabetes.
Results depend on dose progression, adherence, nutrition quality, and activity.
Who typically qualifies?
Clinicians generally follow FDA indications:
BMI ≥30, or
BMI ≥27 with at least one weight-related condition (e.g., hypertension, dyslipidemia, type 2 diabetes).
Medication choice, dosing, and safety screening are individualized.
Safety & side effects (read first)
Common, dose-related effects (often improve with titration): nausea, vomiting, diarrhea/constipation, decreased appetite.
Label warnings include acute pancreatitis, gallbladder disease, potential kidney injury (from dehydration), and gastroparesis-like symptoms.
All GLP-1 class labels carry a boxed warning for thyroid C-cell tumors (observed in rodents). Do not use if you or family have medullary thyroid carcinoma (MTC) or MEN2. Seek urgent care for severe, persistent abdominal pain (possible pancreatitis). Always consult a qualified clinician.
Avoid unapproved products: Stick to FDA-approved meds via licensed providers.
Zepbound vs Wegovy vs Saxenda (quick compare)
Medication | Mechanism | Dosing | Trial-level weight loss* | Notes |
|---|---|---|---|---|
Wegovy (semaglutide) | GLP-1 | Weekly | ~15% at ~68 wks | Well-studied for obesity; step-up dosing improves tolerability. |
Zepbound (tirzepatide) | GIP/GLP-1 | Weekly | ~15–21% at ~72 wks | Dual mechanism; higher doses → greater average loss. |
Saxenda (liraglutide) | GLP-1 | Daily | Lower than above | Older option; pediatric pathway exists in select cases. |
*Population averages from pivotal trials; individual responses vary. Use with nutrition and activity per label.
Ready to plug in the lifestyle piece? Start your plan from your stats
Smarter next steps (with or without meds)
Protein-forward nutrition: Hit a personalized daily target; anchor each meal with protein.
Strength training 2–3×/week: Preserve muscle and metabolic rate during weight loss.
Low-impact cardio (Zone 2): 2–4 sessions/week for recovery, adherence, and heart health.
Hydration & fiber plan: Helps GI comfort during dose titration.
Pairing a medication (if prescribed) with a simple, consistent plan is what sustains results.
Skip the guesswork: Your stats → your plan (free) — calories, macros, meal ideas, workouts, and habit goals tailored to you.
FAQs
Are GLP-1 meds a lifetime commitment?
Obesity is chronic; stopping often leads to partial regain. Some stay on long term with clinical oversight; others transition to structured nutrition/training. Plan for maintenance early.
Can I take GLP-1s if I have thyroid issues?
They’re contraindicated with personal/family history of MTC or MEN2. For other thyroid conditions, consult your clinician.
What starting dose is typical?
Labels use low-and-slow titration (e.g., tirzepatide often begins at 2.5 mg weekly) to improve tolerability—follow your clinician’s plan.
Are there options for teens?
Saxenda has an obesity indication for certain adolescents ≥12 years (>60 kg). Pediatric use requires specialist oversight.
Your stats. Your plan. Start free → onlymeal.io/onboarding
Disclaimer: This article is for educational purposes and not medical advice. Always consult a qualified clinician before starting, stopping, or combining medications and supplements.
